Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $50.39 Analyst target: $75.21 Upside: 49.26%
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development and commercialization of therapies for the treatment of rare diseases. The company is headquartered in San Diego, California.
See the full interactive analysis & chart →Informational only — not investment advice.